Michael J Reardon 1 , David H Adams 2 , Neal S Kleiman 3 , Steven J Yakubov 4 , Joseph S Coselli 5 , G Michael Deeb 6 , Thomas G Gleason 7 , Joon Sup Lee 7 , James B Hermiller 8 , Stan Chetcuti 6 , John Heiser 9 , William Merhi 9 , George L Zorn 10 , Peter Tadros 10 , Newell Robinson 11 , George Petrossian 11 , G Chad Hughes 12 , J Kevin Harrison 12 , Brijeshwar Maini 13 , Mubashir Mumtaz 13 , John V Conte 14 , Jon R Resar 14 , Vicken Aharonian 15 , Thomas Pfeffer 15 , Jae K Oh 16 , Hongyan Qiao 17 , Jeffrey J Popma 18
Jul 14 2015
The U.S. pivotal trial for the self-expanding valve found that among patients with severe aortic stenosis at increased risk for surgery, the 1-year survival rate was 4.9 percentage points higher in patients treated with a self-expanding transcatheter aortic valve bioprosthesis than in those treated with a surgical bioprosthesis.